(Q33410839)

26 July 2017

0 references

Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis (English)

1 reference

26 July 2017

0 references

1 reference

Yuan-Mei He

1

1 reference

26 July 2017

Li Feng

2

1 reference

26 July 2017

Dong-Mei Huo

3

1 reference

26 July 2017

Zhen-Hua Yang

4

1 reference

26 July 2017

Yun-Hua Liao

5

1 reference

26 July 2017

11 October 2013

1 reference

International Urology and Nephrology

26 July 2017

1 reference

26 July 2017

46

1 reference

26 July 2017

2

1 reference

26 July 2017

433-442

1 reference

Oral phosphate binders in patients with kidney failure

26 July 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Consequences and management of hyperphosphatemia in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Hyperphosphatemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Aluminium and bone disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

NAD+ metabolism in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Niacin and analogs for phosphate control in dialysis--perspective from a developing country

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

The effect of niacin on serum phosphorus levels in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

High-density lipoprotein exerts vasculoprotection via endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

High density lipoprotein biogenesis, cholesterol efflux, and immune cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Safety of extended-release niacin/laropiprant in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-013-0559-Z

Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety

21 January 2018

1 reference

12 December 2020

Effectiveness and safety of laropiprant on niacin-induced flushing

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

1 reference

12 December 2020

The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients

1 reference

12 December 2020

Vascular calcification in chronic renal failure

1 reference

12 December 2020

Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.

1 reference

12 December 2020

10.1007/S11255-013-0559-Z

Identifiers

DOI

1 reference

26 July 2017

1 reference